March 21, 2023

Cerevance to Present at Two Medicinal Chemistry Conferences

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Boston, MA – March 21, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.

  • 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
  • Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28 in Cambridge, UK

7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets Conference

Presentation Details

Title: Identification of THIK-1 as a therapeutic target for neuroinflammatory diseases: Discovery and characterisation of a selective THIK-1 blocker

Overview: The NETSseq platform can identify unexplored and druggable microglia targets, exemplified by THIK-1, as potential therapies for neurodegenerative diseases. The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored.

Presenter: Anna Rowland, PhD

Session Date and Time: March 27, 2023, 1:30-2:45pm

Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference

Poster Details

Title :Analysis of the Initial Velocity of Calcium Signalling and β-Arrest in Recruitment at GPR55 with Different Activators Shows Unique Signalling Profiles

Overview: Three proprietary small molecule activators of GPR55 display unique signalling profiles when measuring the initial velocity of calcium and β-arrest in pathway activation.

Presenter: Philip Pickford

Poster Number: 10

About Cerevance

Cerevance is a private pharmaceutical company with a focus on CNS disorders. CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), that demonstrated significant and clinically meaningful efficacy in a 136-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify highly selectively expressed, novel target proteins that are either specific to certain brain circuits or are over- or under-expressed in diseased brains. Partnering with over 25 brain banks and evaluating an expanding collection of more than 12,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit



Johnna Simoes,


Andrew Mielach,, +1-646-876-5868